James E Cassat1,2,3,4,5, Isaac Thomsen1,4. 1. Department of Pediatrics, Division of Pediatric Infectious Diseases. 2. Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center. 3. Department of Biomedical Engineering, Vanderbilt University. 4. Vanderbilt Institute for Infection, Immunology and Inflammation (VI4). 5. Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Abstract
PURPOSE OF REVIEW: Staphylococcus aureus is the most common invasive bacterial pathogen infecting children in the U.S. and many parts of the world. This major human pathogen continues to evolve, and recognition of recent trends in epidemiology, therapeutics and future horizons is of high importance. RECENT FINDINGS: Over the past decade, a relative rise of methicillin-susceptible S. aureus (MSSA) has occurred, such that methicillin-resistant S. aureus (MRSA) no longer dominates the landscape of invasive disease. Antimicrobial resistance continues to develop, however, and novel therapeutics or preventive modalities are urgently needed. Unfortunately, several recent vaccine attempts proved unsuccessful in humans. SUMMARY: Recent scientific breakthroughs highlight the opportunity for novel interventions against S. aureus by interfering with virulence rather than by traditional antimicrobial mechanisms. A S. aureus vaccine remains elusive; the reasons for this are multifactorial, and lessons learned from prior unsuccessful attempts may create a path toward an effective preventive. Finally, new diagnostic modalities have the potential to greatly enhance clinical care for invasive S. aureus disease in children.
PURPOSE OF REVIEW: Staphylococcus aureus is the most common invasive bacterial pathogen infecting children in the U.S. and many parts of the world. This major human pathogen continues to evolve, and recognition of recent trends in epidemiology, therapeutics and future horizons is of high importance. RECENT FINDINGS: Over the past decade, a relative rise of methicillin-susceptible S. aureus (MSSA) has occurred, such that methicillin-resistant S. aureus (MRSA) no longer dominates the landscape of invasive disease. Antimicrobial resistance continues to develop, however, and novel therapeutics or preventive modalities are urgently needed. Unfortunately, several recent vaccine attempts proved unsuccessful in humans. SUMMARY: Recent scientific breakthroughs highlight the opportunity for novel interventions against S. aureus by interfering with virulence rather than by traditional antimicrobial mechanisms. A S. aureus vaccine remains elusive; the reasons for this are multifactorial, and lessons learned from prior unsuccessful attempts may create a path toward an effective preventive. Finally, new diagnostic modalities have the potential to greatly enhance clinical care for invasive S. aureus disease in children.
Authors: Isaac P Thomsen; Priyanka Kadari; Nicole R Soper; Scott Riddell; Deanna Kiska; C Buddy Creech; Jana Shaw Journal: J Pediatr Date: 2019-04-05 Impact factor: 4.406
Authors: Alice G Cheng; Molly McAdow; Hwan K Kim; Taeok Bae; Dominique M Missiakas; Olaf Schneewind Journal: PLoS Pathog Date: 2010-08-05 Impact factor: 6.823
Authors: Qin Yan; Batu K Sharma-Kuinkel; Hitesh Deshmukh; Ephraim L Tsalik; Derek D Cyr; Joseph Lucas; Christopher W Woods; William K Scott; Gregory D Sempowski; Joshua T Thaden; Joshua Thaden; Thomas H Rude; Sun Hee Ahn; Vance G Fowler Journal: PLoS Pathog Date: 2014-06-05 Impact factor: 6.823
Authors: Lloyd S Miller; Vance G Fowler; Sanjay K Shukla; Warren E Rose; Richard A Proctor Journal: FEMS Microbiol Rev Date: 2020-01-01 Impact factor: 16.408
Authors: Hillary Crandall; Aurélie Kapusta; Jarrett Killpack; Carly Heyrend; Kody Nilsson; Mandy Dickey; Judy A Daly; Krow Ampofo; Andrew T Pavia; Matthew A Mulvey; Mark Yandell; Kristina G Hulten; Anne J Blaschke Journal: PLoS One Date: 2020-09-18 Impact factor: 3.240
Authors: Leo Lin; Poochit Nonejuie; Jason Munguia; Andrew Hollands; Joshua Olson; Quang Dam; Monika Kumaraswamy; Heriberto Rivera; Ross Corriden; Manfred Rohde; Mary E Hensler; Michael D Burkart; Joe Pogliano; George Sakoulas; Victor Nizet Journal: EBioMedicine Date: 2015-06-10 Impact factor: 8.143
Authors: Adrienne G Randolph; Ruifei Xu; Tanya Novak; Margaret M Newhams; Juliane Bubeck Wardenburg; Scott L Weiss; Ronald C Sanders; Neal J Thomas; Mark W Hall; Keiko M Tarquinio; Natalie Cvijanovich; Rainer G Gedeit; Edward J Truemper; Barry Markovitz; Mary E Hartman; Kate G Ackerman; John S Giuliano; Steven L Shein; Kristin L Moffitt Journal: Clin Infect Dis Date: 2019-01-18 Impact factor: 9.079
Authors: Alex van Belkum; Till T Bachmann; Gerd Lüdke; Jan Gorm Lisby; Gunnar Kahlmeter; Allan Mohess; Karsten Becker; John P Hays; Neil Woodford; Konstantinos Mitsakakis; Jacob Moran-Gilad; Jordi Vila; Harald Peter; John H Rex; Wm Michael Dunne Journal: Nat Rev Microbiol Date: 2019-01 Impact factor: 60.633
Authors: Selvi C Ersoy; Adhar C Manna; Arnold S Bayer; Ambrose Cheung; Richard A Proctor; Henry F Chambers; Ewan M Harrison Journal: Antimicrob Agents Chemother Date: 2022-05-16 Impact factor: 5.938